Terumo India introduces advanced liver cancer treatments Occlusafe and LifePearl

Terumo India introduces advanced liver cancer treatments Occlusafe and LifePearl

Terumo India, the Indian subsidiary of the globally recognized Terumo Corporation, has recently announced the launch of two innovative products, Occlusafe and LifePearl, aimed at enhancing the management of liver cancer. This introduction marks a significant advancement in the Indian healthcare sector, especially for the treatment of hepatocellular carcinoma (HCC), the most prevalent type of […]

Your diet soda could be deadly: What international agencies say about Aspartame

Your diet soda could be deadly: What international agencies say about Aspartame

the International Agency for Research on Cancer (IARC) and the Joint Expert Committee on Food Additives (JECFA), of the World Health Organization (WHO) and the Food and Agriculture Organization (FAO), issued assessments regarding the health impacts of the non-sugar sweetener aspartame. These agencies cited limited evidence linking aspartame to carcinogenicity in humans, leading to IARC […]

AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study

AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study

AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the updated results from the HIMALAYA Phase 3 trial. An unparalleled one in four patients were still alive four years after treatment with this novel combination therapy, marking the longest survival […]

SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer

SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer

In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with Hong Kong-based Lee’s Pharmaceutical, has announced the enrollment of the first patient in China for their phase 3 trial, named PHOCUS. This trial will assess the oncolytic immunotherapy Pexa-Vec for the treatment of advanced liver cancer and […]